NCT02347111View on ClinicalTrials.gov

Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation

PHASE4RecruitingINTERVENTIONAL
Enrollment

162

Participants

Timeline

Start Date

December 31, 2020

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Atrial Fibrillation
Interventions
DRUG

Flecainide

flecainide up to 150mg twice daily for the control of atrial fibrillation

DRUG

Sotalol

sotalol up to 120mg twice daily for the control of atrial fibrillation

Trial Locations (4)

60453

NOT_YET_RECRUITING

Advocate Christ Medical Center, Oak Lawn

60612

NOT_YET_RECRUITING

Jesse Brown VA Medical Center, Chicago

NOT_YET_RECRUITING

Rush University Medical Center, Chicago

RECRUITING

University of Illinois at Chicago, Chicago

Sponsors

Collaborators (1)

Medtronic
All Listed Sponsors
collaborator

Medtronic

INDUSTRY

lead

University of Illinois at Chicago

OTHER